We identified potential drug targets for high‐risk ccRCC patients from the GDSC database, mainly including transforming growth factor‐β (TGF‐β) receptor inhibitors (A‐83‐01, SB52334, SB505124), Brutinib tyrosine kinase (BTK) inhibitors (Ibrutinib), apoptosis related (Sinularin), insulin‐like growth factor‐1 (IGF1) receptor inhibitor (Linsitinib, BMS‐754807), and tyrosine kinase inhibitor (Cediranib). The gene discussed is BTK; the disease is nonpapillary renal cell carcinoma.